Two named fixes for antipsychotic metabolic syndrome sit outside the guideline
- Source and genre. Psychiatrist Natalia Petrova published a literature review in Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2024;124(8):13-20, DOI 10.17116/jnevro202412408113, online 13 September 2024. Drawing on PubMed and Google Scholar, the review surveyed 24 pharmacological interventions used against metabolic syndrome (MetS) in patients on antipsychotics. It is a literature review, not a clinical guideline.
- Metformin, at 1000-1500 mg per day, is named the most studied of the 24 interventions for preventing or reducing antipsychotic-related metabolic disturbance.
- The review's other route is switching the antipsychotic itself to an agent with lower metabolic risk, aripiprazole named first, with amisulpride and sulpiride as alternatives. It cites a Russian clinical sample: 62 patients with schizophrenia, overweight from atypical antipsychotics taken during drug remission, switched to aripiprazole, with a significant reduction in weight, in some cases to normal.
- MetS itself is defined in the review by five diagnostic criteria: waist circumference, triglycerides, HDL cholesterol, blood pressure, fasting glucose. The excerpt available for this note carries no monitoring schedule by time interval.
A patient on an atypical antipsychotic develops the full picture of metabolic syndrome (MetS) - expanding waist circumference, rising triglycerides, falling HDL cholesterol, climbing blood pressure, fasting glucose drifting upward. What should the treating psychiatrist do next? A 2024 literature review in the Korsakov Journal names two answers. The clinical guideline that has governed Russian psychiatric practice since 1 January 2025 names neither.
A review, not a protocol
The paper is worth reading with its genre in mind. Psychiatrist Natalia Petrova surveyed published randomized trials, meta-analyses and systematic reviews indexed in PubMed and Google Scholar, and organized the material around MetS prevalence, mechanisms and correction in patients on antipsychotics. It carries no guideline status and issues no formal recommendations - it is one author's synthesis of the literature, naming 24 separate pharmacological interventions tried against antipsychotic-related metabolic disturbance.
Two named fixes
Of the 24, metformin (1000-1500 mg per day) is singled out as the most studied. The second route is switching the antipsychotic itself to an agent with lower metabolic liability - aripiprazole first, with amisulpride and sulpiride as alternatives. Part of the case for aripiprazole is mechanistic: the review attributes its comparatively favorable metabolic profile in part to partial agonism at the 5-HT1A receptor, which it suggests offsets effects otherwise carried through 5-HT2C, and it reports that over six months the risk of clinically significant weight gain, new-onset diabetes, or dyslipidemia on aripiprazole was comparable to placebo in the trials it drew on.
The review anchors the switching claim in a Russian clinical sample: 62 patients with schizophrenia, overweight from atypical antipsychotics taken during drug remission, were moved to aripiprazole, with a significant reduction in weight, in some cases back to normal range. For a patient who has crossed into type 2 diabetes or sustained hyperglycemia, the review names the same first step - switching to aripiprazole - before any other pharmacological correction.
What the guideline asks for instead
The guideline "Schizophrenia," approved by the Russian Ministry of Health on 22 October 2024 and in force from 1 January 2025, sets a narrower bar for metabolic monitoring: measuring lipids and glucose, at evidence level 5 and recommendation strength C, the lowest tiers the document uses anywhere. It does not mention metformin. It does not describe a switching algorithm. A psychiatrist who follows the guideline to the letter tests for MetS; a psychiatrist who follows the review corrects it. Nothing in the review says the guideline is wrong, and nothing in the guideline says the review is right - the two documents answer different questions, and the gap between them is where a treating clinician currently decides alone.
The guideline in force since January 2025 tells a psychiatrist how to test for metabolic syndrome; a 2024 literature review is what tells one how to treat it.
This is a narrative literature review by a single author, not a systematic review with a registered protocol, a meta-analysis, or a clinical guideline - it carries no formal grading of the underlying evidence. The Russian n=62 switching sample is described in the review at the level of outcome (significant weight reduction) without the trial design, comparator or follow-up interval given in the excerpt available for this note.